Possibilities and limits of ovarian reserve testing in ART

Current Pharmaceutical Biotechnology

Volumn 13, Issue 3, 2012, Pages 398-408

  la Marca, Antonio ^a,b   Argento, Cindy ^a,b   Sighinolfi, Giovanna ^a,b   Grisendi, Valentina ^a,b   Carbone, Marilena ^a,b   D'Ippolito, Giovanni ^a,b   Artenisio, Alfredo Carducci ^a,b   Stabile, Gaspare ^a,b   Volpe, Annibale ^a,b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

AFC; AMH; ART; FSH; Hyperresponse; IVF; OHSS; Ovarian reserve; Poor response

Indexed keywords

CLOMIFENE CITRATE; ESTRADIOL; FOLLITROPIN; GONADOTROPIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN;

ARTICLE; FEMALE FERTILITY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FOLLICULAR PHASE; HORMONAL REGULATION; HUMAN; LIVE BIRTH; MENSTRUAL CYCLE; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY FOLLICLE; OVULATION INDUCTION; PREDICTIVE VALUE; PREMATURE OVARIAN FAILURE; REPRODUCTION; VASCULARIZATION;

ADULT; ANTI-MULLERIAN HORMONE; COST-BENEFIT ANALYSIS; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY, FEMALE; INHIBINS; MIDDLE AGED; OOCYTES; OVARIAN FOLLICLE; OVARIAN FUNCTION TESTS; OVARY; OVULATION INDUCTION;

EID: 84857700391     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799361972     Document Type: Article

References (81)

1. [Spira, A. The decline of fecundity with age. Maturitas, 1988, (Suppl. 1), 15-22.
2. [Wood, J.W. Fecundity and natural fertility in humans. Oxf. Rev. Reprod. Biol., 1989, 11, 61-109. Review.
3. Templeton, A.; Morris, J.K.; Parslow, W. Factors that affect outcome of in-vitro fertilisation treatment. Lancet, 1996, 348(9039), 1402-1406.
4. [te Velde, E.R.; Pearson, P.L. The variability of female reproductive ageing. Hum. Reprod. Update, 2002, 8(2), 141-154. Review.
5. La Marca, A.; Sighinolfi, G.; Radi, D.; Argento, C.; Baraldi, E.; Artenisio, A.C.; Stabile, G.; Volpe, A. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum. Reprod. Update, 2010, 16(2), 113-130.
6. Gnoth, C.; Schuring, A.N.; Friol, K.; Tigges, J.; Mallmann, P.; Godehardt, E. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum. Reprod., 2008, 23(6), 1359-1365.
7. Nelson, S.M.; Yates, R.W.; Lyall, H.; Jamieson, M.; Traynor, I.; Gaudoin, M.; Mitchell, P.; Ambrose, P.; Fleming, R. Anti- Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum. Reprod., 2009, 24(4), 867-875
8. Markström, E.; Svensson, E.Ch.; Shao, R.; Svanberg, B.; Billig, H. Survival factors regulating ovarian apoptosis-dependence on follicle differentiation. Reproduction, 2002, 123(1), 23-30.
9. Faddy, M.J. Follicle dynamics during ovarian ageing. Mol. Cell. Endocrinol., 2000, 163(1-2), 43-48.
10. Haadsma, M.L.; Groen, H.; Mooij, T.M.; Burger, C.W.; Broekmans, F.J.; Lambalk, C.B.; Leeuwen, F.E.; Hoek, A. OMEGA Project Group. Miscarriage risk for IVF pregnancies in poor responders to ovarian hyperstimulation. Reprod. Biomed. Online, 2010, 20(2), 191-200.
11. Haadsma, M.L.; Mooij, T.M.; Groen, H.; Burger, C.W.; Lambalk, C.B.; Broekmans, F.J.; van Leeuwen, F.E.; Bouman, K.; Hoek, A. OMEGA Project Group. A reduced size of the ovarian follicle pool is associated with an increased risk of a trisomic pregnancy in IVFtreated women. Hum. Reprod., 2010, 25(2), 552-558.
12. Broekmans, F.J.; Kwee, J.; Hendriks, D.J.; Mol, B.W.; Lambalk, C.B. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update, 2006, 12(6), 685-718.
13. van der Steeg, J.W.; Steures, P.; Eijkemans, M.J.; Habbema, J.D.; Hompes, P.G.; Broekmans, F.J.; Bouckaert, P.X.; Bossuyt, P.M.; van der Veen, F.; Mol, B.W. Predictive value and clinical impact of Basal follicle-stimulating hormone in subfertile, ovulatory women. J. Clin. Endocrinol. Metab., 2007, 92(6), 2163-2168.
14. Klinkert, E.R.; Broekmans, F.J.; Looman, C.W.; Te Velde, E.R. A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cycles. Fertil. Steril., 2004, 81(5), 1247-1253.
15. van Disseldorp, J.; Eijkemans, M.J.; Klinkert, E.R.; te Velde, E.R.; Fauser, B.C.; Broekmans, F.J. Cumulative live birth rates following IVF in 41- to 43-year-old women presenting with favourable ovarian reserve characteristics. Reprod. Biomed. Online., 2007, 14(4), 455-463.
16. van Montfrans, J.M.; Hoek, A.; van Hooff, M.H.; de Koning, C.H.; Tonch, N.; Lambalk, C.B. Predictive value of basal folliclestimulating hormone concentrations in a general subfertility population. Fertil. Steril., 2000, 74(1), 97-103.
17. Bancsi, L.F.; Broekmans, F.J.; Mol, B.W.; Habbema, J.D.; te Velde, E.R. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: a meta-analysis. Fertil. Steril., 2003, 79(5), 1091-1100.
18. Groome, N.P.; Illingworth, P.J.; O'Brien, M.; Cooke, I.; Ganesan, T.S.; Baird, D.T.; McNeilly, A.S. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin. Endocrinol. (Oxf), 1994, 40(6), 717-723.
19. Hall, J.E.; Welt, C.K.; Cramer, D.W. Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome. Hum. Reprod., 1999, 14(2), 409-415.
20. Seifer, D.B.; Lambert-Messerlian, G.; Hogan, J.W.; Gardiner, A.C.; Blazar, A.S.; Berk, C.A. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil. Steril., 1997, 67(1), 110-114.
21. Scheffer, G.J.; Broekmans, F.J.; Looman, C.W.; Blankenstein, M.; Fauser, B.C.; teJong, F.H.; te Velde, E.R. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum. Reprod., 2003, 18(4), 700-706.
22. van Rooij, I.A.; Broekmans, F.J.; Scheffer, G.J.; Looman, C.W.; Habbema, J.D.; de Jong, F.H.; Fauser, B.J.; Themmen, A.P.; te Velde, E.R. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil. Steril., 2005, 83(4), 979-987.
23. Burger, H.G.; Hale, G.E.; Robertson, D.M.; Dennerstein, L. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum. Reprod. Update, 2007, 13(6), 559-565.
24. Vigier, B.; Tran, D.; Legeai, L.; Bézard, J.; Josso, N. Origin of anti- Müllerian hormone in bovine freemartin fetuses. J. Reprod. Fertil., 1984, 70(2), 473-479.
25. La Marca, A.; Volpe, A. Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin. Endocrinol. (Oxf), 2006, 64(6), 603-610.
26. La Marca, A.; Broekmans, F.J.; Volpe, A.; Fauser, B.C.; Macklon, N.S. ESHRE special interest group for reproductive endocrinology- AMH round table. Anti-mullerian hormone (AMH): what do we still need to know? Hum. Reprod., 2009, 24(9), 2264-2275.
27. La Marca, A.; De Leo, V.; Giulini, S.; Orvieto, R.; Malmusi, S.; Giannella, L.; Volpe, A. Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause. J. Soc. Gynecol. Investig., 2005, 12(7), 545-548.
28. van Disseldorp, J.; Faddy, M.J.; Themmen, A.P.; de Jong, F.H.; Peeters, P.H.; van der Schouw, Y.T.; Broekmans, F.J. Relationship of serum antimüllerian hormone concentration to age at menopause. J. Clin. Endocrinol. Metab., 2008, 93(6), 2129-2134.
29. Tehrani, F.R.; Solaymani-Dodaran, M.; Azizi, F. A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. Menopause, 2009, 16(4), 797-802.
30. van Rooij, I.A.; Tonkelaar, I.; Broekmans, F.J.; Looman, C.W.; Scheffer, G.J.; de Jong, F.H.; Themmen, A.P.; te Velde, E.R. Antimüllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause, 2004, 11(6 pt. 1), 601-606.
31. La Marca, A.; Sighinolfi, G.; Giulini, S.; Traglia, M.; Argento, C.; Sala, C.; Masciullo, C.; Volpe, A.; Toniolo, D. Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles. Reprod. Biomed. Online, 2010, 21(4), 463-469.
32. Anderson, R.A.; Themmen, A.P.; Al-Qahtani, A.; Groome, N.P.; Cameron, D.A. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum. Reprod., 2006, 21(10), 2583-2592.
33. Sowers, M.R.; Eyvazzadeh, A.D.; McConnell, D.; Yosef, M.; Jannausch, M.L.; Zhang, D.; Harlow, S.; Randolph, J.F.Jr. Antimullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J. Clin. Endocrinol. Metab., 2008, 93(9), 3478-3483.
34. Soto, N.; Iñiguez, G.; López, P.; Larenas, G.; Mujica, V.; Rey, R.A.; Codner, E. Anti-Mullerian hormone and inhibin B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes mellitus. Hum. Reprod., 2009, 24(11), 2838-2844.
35. Nelson, S.M.; Messow, M.C.; Wallace, A.M.; Fleming, R.; McConnachie, A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. Fertil. Steril., 2010, 95(2),736-741.
36. Seifer, D.B.; Baker, V.L.; Leader, B. Age-specific serum anti- Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil. Steril., 2010, 95(2), 747-750.
37. Shebl, O.; Ebner, T.; Sir, A.; Schreier-Lechner, E.; Mayer, R.B.; Tews, G.; Sommergruber, M. Age-related distribution of basal serum AMH level in women of reproductive age and a presumably healthy cohort. Fertil. Steril., 2010, 95(2), 832-834.
38. Knauff, E.A.; Eijkemans, M.J.; Lambalk, C.B.; ten Kate-Booij, M.J.; Hoek, A.; Beerendonk, C.C.; Laven, J.S.; Goverde, A.J.; Broekmans, F.J.; Themmen, A.P.; de Jong, F.H.; Fauserm B.C. Dutch Premature Ovarian Failure Consortium. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J. Clin. Endocrinol. Metab., 2009, 94(3), 786-792.
39. La Marca, A.; Giulini, S.; Tirelli, A.; Bertucci, E.; Marsella, T.; Xella, S.; Volpe, A. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum. Reprod., 2007, 22(3), 766-771.
40. Nelson, S.M.; Yates, R.W.; Fleming, R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy. Hum. Reprod., 2007, 22(9), 2414-2421.
41. Fanchin, R.; Louafi, N.; Méndez Lozano, D.H.; Frydman, N.; Frydman, R.; Taieb, J. Per-follicle measurements indicate that antimüllerian hormone secretion is modulated by the extent of follicular development and luteinization and may reflect qualitatively the ovarian follicular status. Fertil. Steril., 2005, 84(1), 167-173.
42. Fanchin, R.; Mendez Lozano, D.H.; Frydman, N.; Gougeon, A.; di Clemente, N.; Frydman, R.; Taieb, J. Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J. Clin. Endocrinol. Metab., 2007, 92(5), 1796-1802.
43. Broer, S.L.; Mol, B.W.; Hendriks, D.; Broekmans, F.J. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil. Steril., 2009, 91(3), 705-714.
44. [La Marca, A.; Nelson, S.M; Sighinolfi, G.; Manno, M.; Baraldi, E.; Roli, L.; Xella, S.; Marsella, T.; Tagliasacchi, D.; D'Amico, R.; Volpe, A. Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. Reprod. Biomed. Online, 2010, [in press].
45. Gougeon, A. Ovarian follicular growth in humans: ovarian ageing and population of growing follicles. Maturitas, 1998, 30(2), 137-142.
46. Broekmans, F.J.; de Ziegler, D.; Howles, C.M.; Gougeon, A.; Trew, G.; Olivennes, F. The antral follicle count: practical recommendations for better standardization. Fertil. Steril., 2010, 94(3), 1044-1051.
47. Broekmans, F.J.; Faddy, M.J.; Scheffer, G.; te Velde, E.R. Antral follicle counts are related to age at natural fertility loss and age at menopause. Menopause, 2004, 11(6 pt. 1), 607-614.
48. [La Marca, A.; Spada, E.; Sighinolfi, G.; Argento, C.; Tirelli, A.; Giulini, S.; Milani, S.; Volpe, A. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. Fertil. Steril., 24th Aug 2010. [in press].
49. [Broer, S.L.; Dólleman, M.; Opmeer, B.C.; Fauser, B.C.; Mol, B.W.; Broekmans, F.J. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum. Reprod. Update, 28th Jul 2010. [in press]
50. Maseelall, P.B.; Hernandez-Rey, A.E.; Oh, C.; Maagdenberg, T.; McCulloh, D.H.; McGovern, P.G. Antral follicle count is a significant predictor of livebirth in in vitro fertilization cycles. Fertil. Steril., 2009, 91(Suppl. 4), 1595-1597.
51. Syrop, C.H.; Dawson, J.D.; Husman, K.J.; Sparks, A.E.; Van Voorhis, B.J. Ovarian volume may predict assisted reproductive outcomes better than follicle stimulating hormone concentration on day 3. Hum. Reprod., 1999, 14(7), 1752-1756.
52. Chui, D.K.; Pugh, N.D.; Walker, S.M.; Gregory L.; Shaw, R.W. Follicular vascularity-the predictive value of transvaginal power Doppler ultrasonography in an in-vitro fertilization programme: a preliminary study. Hum. Reprod., 1997, 12(1), 191-196.
53. Kim, S.H.; Ku, S.Y.; Jee, B.C; Suh, C.S.; Moon, S.Y.; Lee, J.Y. Clinical significance of transvaginal color Doppler ultrasonography of the ovarian artery as a predictor of ovarian response in controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer. J. Assist. Reprod. Genet., 2002, 19(3), 103-112.
54. Navot, D.; Rosenwaks, Z.; Margalioth, E.J. Prognostic assessment of female fecundity. Lancet, 1987, 2(8560), 645-647.
55. Hendriks, D.J.; Broekmans, F.J.; Bancsi, L.F.; de Jong, F.H.; Looman, C.W.; te Velde, E.R. Repeated clomiphene citrate challenge testing in the prediction of outcome in IVF: a comparison with basal markers for ovarian reserve. Hum. Reprod., 2005, 20(1), 163-169.
56. Watt, A.H.; Legedza, A.T.; Ginsburg, E.S.; Barbieri, R.L.; Clarke, R.N.; Hornstein, M.D. The prognostic value of age and folliclestimulating hormone levels in women over forty years of age undergoing in vitro fertilization. J. Assist. Reprod. Genet., 2000, 17(5), 264-268.
57. Ranieri, D.M.; Quinn, F.; Makhlouf, A.; Khadum, I.; Ghutmi, W.; McGarrigle, H.; Davies, M.; Serhal, P. Simultaneous evaluation of basal follicle-stimulating hormone and 17 beta-estradiol response to gonadotropin-releasing hormone analogue stimulation: an improved predictor of ovarian reserve. Fertil. Steril., 1998, 70(2), 227-233.
58. Fanchin, R.; de Ziegler, D.; Olivennes, F.; Taieb, J.; Dzik, A.; Frydman, R. Exogenous follicle stimulating hormone ovarian reserve test (EFORT): a simple and reliable screening test for detecting 'poor responders' in in-vitro fertilization. Hum. Reprod., 1994, 9(9), 1607-1611.
59. Kwee, J.; Schats, R.; McDonnell, J.; Schoemaker, J.; Lambalk, C.B. The clomiphene citrate challenge test versus the exogenous follicle-stimulating hormone ovarian reserve test as a single test for identification of low responders and hyperresponders to in vitro fertilization. Fertil. Steril., 2006, 85(6), 1714-1722.
60. Broekmans, F.J.; Soules, M.R.; Fauser, B.C. Ovarian aging: mechanisms and clinical consequences. Endocr. Rev., 2009, 30(5), 465-493.
61. Brodin, T.; Bergh, T.; Berglund, L.; Hadziosmanovic, N.; Holte, J. Menstrual cycle length is an age-independent marker of female fertility: results from 6271 treatment cycles of in vitro fertilization. Fertil. Steril., 2008, 90(5), 1656-1661.
62. Lambalk, C.B.; de Koning, C.H.; Flett, A.; Van Kasteren, Y.; Gosden, R.; Homburg, R. Assessment of ovarian reserve. Ovarian biopsy is not a valid method for the prediction of ovarian reserve. Hum. Reprod., 2004, 19(5), 1055-1059.
63. Verhagen, T.E.; Hendriks, D.J.; Bancsi, L.F.; Mol, B.W.; Broekmans, F.J. The accuracy of multivariate models predicting ovarian reserve and pregnancy after in vitro fertilization: a meta-analysis. Hum. Reprod. Update, 2008, 14(2), 95-100.
64. Hanoch, J.; Lavy, Y.; Holzer, H.; Hurwitz, A.; Simon, A.; Revel, A.; Laufer, N. Young low responders protected from untoward effects of reduced ovarian response. Fertil. Steril., 1998, 69(6), 1001-1004.
65. [Pandian, Z.; McTavish, A.R.; Aucott, L.; Hamilton, M.P.; Bhattacharya, S. Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst. Rev., 20th Jan 2010, (1).
66. Venetis, C.A.; Kolibianakis, E.M.; Tarlatzi, T.B.; Tarlatzis, B.C. Evidence-based management of poor ovarian response. Ann. N. Y. Acad. Sci., 2010, 1205, 199-206.
67. [Tarlatzis, B.C.; Zepiridis, L.; Grimbizis, G.; Bontis, J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum. Reprod. Update, 2003, 9(1), 61-76. Review.
68. Karande, V.C.; Jones, G.S.; Veeck, L.L.; Muasher, S.J. High-dose follicle-stimulating hormone stimulation at the onset of the menstrual cycle does not improve the in vitro fertilization outcome in low-responder patients. Fertil. Steril., 1990, 53(3), 486-489.
69. Land, J.A.; Yarmolinskaya, M.I.; Dumoulin, J.C.; Evers, J.L. Highdose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil. Steril., 1996, 65(5), 961-965.
70. Cedrin-Durnerin, I.; Bständig, B.; Hervé, F.; Wolf, J.; Uzan, M.; Hugues, J. A comparative study of high fixed-dose and decremental- dose regimens of gonadotropins in a minidose gonadotropinreleasing hormone agonist flare protocol for poor responders. Fertil. Steril., 2000, 73(5), 1055-1056.
71. Klinkert, E.R.; Broekmans, F.J.; Looman, C.W.; Habbema, J.D.; te Velde, E.R. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum. Reprod., 2005, 20(3), 611-615.
72. Lekamge, D.N.; Lane, M.; Gilchrist, R.B.; Tremellen, K.P. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. J. Assist. Reprod. Genet., 2008, 25(11-12), 515-521.
73. [Eskandar, M.; Jaroudi, K.; Jambi, A.; Archibong, E.I.; Coskun, S.; Sobande, A.A. Is recombinant follicle-stimulating hormone more effective in IVF poor responders than human menopausal gonadotrophins? Med. Sci. Monit., 2004, 10(1), PI6-PI9.
74. Ubaldi, F.M.; Rienzi, L.; Ferrero, S.; Baroni, E.; Sapienza, F.; Cobellis, L.; Greco, E. Management of poor responders in IVF. Reprod. Biomed. Online, 2005, 10(2), 235-246.
75. Loutradis, D.; Vomvolaki, E.; Drakakis, P. Poor responder protocols for in-vitro fertilization: options and results. Curr. Opin. Obstet. Gynecol., 2008, 20(4), 374-378.
76. Verberg, M.F.; Macklon, N.S.; Nargund, G.; Frydman, R.; Devroey, P.; Broekmans, F.J.; Fauser, B.C. Mild ovarian stimulation for IVF. Hum. Reprod. Update, 2009, 15(1), 13-29.
77. Heijnen, E.M.; Eijkemans, M.J.; De Klerk, C.; Polinder, S.; Beckers, N.G.; Klinkert, E.R.; Broekmans, F.J.; Passchier, J.; Te Velde, E.R.; Macklon, N.S.; Fauser, B.C. A mild treatment strategy for invitro fertilisation: a randomised non-inferiority trial. Lancet, 2007, 369(9563), 743-749.
78. Heijnen, E.M.; Macklon, N.S.; Fauser, B.C. What is the most relevant standard of success in assisted reproduction? The next step toimproving outcomes of IVF: consider the whole treatment. Hum. Reprod., 2004, 19(9), 1936-1938.
79. Humaidan, P.; Quartarolo, J.; Papanikolaou, E.G. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil. Steril., 2010, 94(2), 389-400.
80. Humaidan, P.; Papanikolaou, E.G.; Tarlatzis, B.C. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum. Reprod., 2009, 24(10), 2389-2394.
81. Griesinger, G.; Diedrich, K.; Devroey, P.; Kolibianakis, E.M. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum. Reprod. Update, 2006, 12(2), 159-168.